AnaptysBio subleases 45,057 sq ft of HQ to First Tracks for up to ~22 months

ANAPTYSBIO, INC

Sublease of 45,057 rentable sq ft at 10770 Wateridge Circle, San Diego, for 12-month initial term starting June 15, 2026.
First Tracks has option to extend term until April 4, 2028 (max ~22 months) and can terminate with 3 months' notice.
Sublessee pays Basic Rent plus Additional Rent under master lease; AnaptysBio remains primarily liable to master landlord.
Sublease is subordinate to master lease; AnaptysBio cannot terminate or amend master lease without First Tracks' consent (except for its own termination option).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ANAPTYSBIO, INC entered into Sublease Agreement with First Tracks Biotherapeutics, Inc. valued at monthly rent equal to the monthly Basic Rent and Additional Rent owed by the Company under the Maste (effective 2026-06-15).

Action: entry
Agreement: lease
Counterparty: First Tracks Biotherapeutics, Inc.
Value: monthly rent equal to the monthly Basic Rent and Additional Rent owed by the Company under the Maste
Effective: 2026-06-15

Exact text from the filing

On June 15, 2026, AnaptysBio, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with First Tracks Biotherapeutics, Inc., a Delaware corporation (“First Tracks”), pursuant to which the Company agreed to sublease to First Tracks approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121 (the “Premises”).

View on SEC.gov

627 material agreements filed in the last 30 days. Browse all material agreements →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001193125-26-277505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.